MRCM
LGND icon

M&R Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

M&R Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$200K Hold
2,000
– – 0.04% 132
2024
Q2 		$169K Hold
2,000
– – 0.04% 139
2024
Q1 		$146K Buy
+2,000
New +$147K 0.04% 148

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return

M&R Capital Management's LGND Position: Q3 2024 in Review

M&R Capital Management held its Ligand Pharmaceuticals (LGND) position steady in Q3 2024 at 2,000 shares worth $200K. The position accounts for 0.04% of the portfolio, ranked #132.

M&R Capital Management first reported a position in LGND in Q1 2024 and has held it in 3 quarters since. 243 funds tracked by Wall St. Rank hold LGND as of Q3 2024.

  • M&R Capital Management held 2,000 shares of Ligand Pharmaceuticals worth $200K as of Q3 2024.
  • M&R Capital Management left its Ligand Pharmaceuticals share count unchanged in Q3 2024.
  • Ligand Pharmaceuticals made up 0.04% of M&R Capital Management's portfolio in Q3 2024, its #132 holding.
  • M&R Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 243 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2024.

Based on M&R Capital Management's 13F filing for Q3 2024, filed 2 Oct 2024.